NEW YORK, NY / ACCESSWIRE / August 9, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Predictive Oncology. Mark Roberts, Senior Editor at Traders News Source had the opportunity to conduct the interview featuring J. Melville Engle, CEO and Chairman of the Board, Predictive Oncology.
Mark had the pleasure of recently conducting the Interview with J. Melville Engle Chief Executive Officer at Predictive Oncology Inc. (NASDAQ:POAI). Mr. Roberts diligently focused on questions he thought would be on the minds of most current and potential future shareholders. See interview highlights below.
Access this interview in its entirety at https://tradersnewssource.com/poai-ceo-interview/
Mr. Engle became POAI's CEO in 2021 and was appointed to the POAI Board of Directors in 2016. He was elected Chairman of the Board in 2020.
Before Predictive Oncology
Between 2012 and 2021, he was CEO of Engle Strategic Solutions, a consulting and coaching company focused on CEO issues. From 2009 to 2012, he was CEO and Chairman of Thermogenesis, a cell separation company. From 2002 to 2007, he was Regional Head/Director, North America at Merck Generics and CEO of Dey Laboratories, a respiratory company. From 1996 to 2001, he was CEO and Chairman of Anika Therapeutics, an orthobiologics company. From 1980 to 1995, he was with Allergan, Inc., an eye and skin care company, where he served as CFO, Managing Director (living in Toronto), and other positions with the firm.
"Eliminating cancer is our overall goal. This is not an easy task. We are working hard every day to make this happen, using our novel technology and talented team of employees."
Education
University of Southern California
School of Business
MBA, Finance
University of Colorado Boulder
BS, Accounting
Interview Highlights:
Traders News Source Editor Mark Roberts covers the future vision for the company, the patent portfolio, current cash runway, what Mr. Engle has to say to investors that could encourage a higher value for the company plus much more in this interview.
Access this interview in its entirety at https://tradersnewssource.com/poai-ceo-interview/
About Predictive Oncology
Predictive Oncology (NASDAQ:POAI) is a knowledge-driven company focused on applying artificial intelligence (AI) to develop optimal cancer therapies, which can lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a database of 150,000+ cancer tumors, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success. The company offers a suite of solutions for oncology drug development from early discovery to clinical trials.
Public Relations Contact:
Predictive Oncology
Theresa Ferguson
630-566-2003
tferguson@predictive-oncology.com
Investor Relations Contact:
Landon Capital
Keith Pinder
(404) 995-6671
kpinder@landoncapital.net
About Traders News Source (TNS)
Traders News Source is a leading independent equity research and corporate access firm focused on finding and reporting on the next hot stocks and market sectors prior to a significant move. TNS is also a financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. Our C-level interviews answer some of the hard-hitting questions that rest on the minds of most current and future shareholders. TNS C-level interviews provide valuable insights into the operations and management direction of some of the most promising small and mid-cap publicly traded companies. To review TNS disclosure statement please visit: https://tradersnewssource.com/poai-ceo-interview/
Media Contact
Traders News Source
Mark Roberts, Senior Editor/Interviewer Editor@TradersNewsSource.com
or Call Paul Lipp, President TNS LLC at +1-810-618-1023
SOURCE: Traders News Source LLC
View source version on accesswire.com:
https://www.accesswire.com/711300/Traders-News-Source-Senior-Editor-Mark-Roberts-Interviews-J-Melville-Engle-CEO-and-Chairman-of-the-Board-Predictive-Oncology
